Halayen Aiki
Ƙimar Ganewa: 5ng/ml;
Matsakaicin iyaka: 5.00 ~ 400.00 ng/ml;
Matsakaicin daidaituwa na layi R ≥0.990;
Daidaitawa: a cikin tsari CV shine ≤15%;tsakanin batches CV shine ≤20%;
Daidaito: bambancin dangi na sakamakon auna bazai wuce ± 15% ba lokacin da aka gwada daidaitaccen ma'auni.
1. Ajiye ma'aunin ganowa a 2～30℃.Matsakaicin ya tsaya tsayin daka har zuwa watanni 18.
2. Adana kaset ɗin gwajin sauri na Aehealth Ferritin a 2～30 ℃, rayuwar rayuwar ta kasance har zuwa watanni 18.
3. Ya kamata a yi amfani da kaset na gwaji a cikin awa 1 bayan buɗe fakitin.
ST2 memba ne na Toll-like receptor / interleukin-1 (interleukin-1, IL-1) superfamily mai karɓa.IL-33 shine ƙayyadaddun ligand na aiki kuma an ɓoye shi ta hanyar cardiomyocytes da fibroblasts.Samfura guda biyu na maganganun kwayoyin halitta: transmembrane ST2 (ST2L) da sST2.ST2L ya ƙunshi yanki na immunoglobulin extracellular guda uku, yayin da sST2 ba shi da transmembrane da yanki mai karɓa na ciki.Suna ɗaure ga ligand gama gari IL-33 kuma suna taka rawar nazarin halittu.Hanyoyin siginar ST2L da IL-33 suna da tasirin cututtukan zuciya irin su anti-cardiomyocyte hypertrophy, fibrosis na myocardial da anti-atherosclerosis.Lokacin da nauyin zuciya ya karu, ƙaddamarwar sST2 yana ƙaruwa, kuma ƙarar sST2 yana hana IL-33 daga haɗuwa tare da ST2L, ta haka yana tsayayya da tasirin cardioprotective na IL-33 / ST2L hanyar sigina.An yi la'akari da cewa sST2 na iya zama mai shiga tsakani na cututtuka na cardiomyocyte hypertrophy da fibrosis na myocardial.Ƙayyadaddun ƙididdiga na matakan sST2 na iya ba wa likitocin kayan aiki daidai don taimakawa wajen tantance ciwon zuciya.